Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Zenz

Showing results (1-10 of 183) with videos related to

Pageof 19
Sort By:
Blood|March 2, 2013
Exhausting T cells in CLLThorsten Zenz
Blood|October 31, 2015
Mutational landscape and complexity in CLLThorsten Zenz, Wolfgang Huber
British Journal of Haematology|June 13, 2022
GOALs in relapsed DLBCLWiebke Rösler, Thorsten Zenz
Leukemia & Lymphoma|August 16, 2012
Improving treatment for chronic lymphocytic leukemia by rational use of monoclonal antibodiesMikołaj Słabicki, Thorsten Zenz
Blood|August 14, 2010
CLL 17p deletion: more than 'miR'ly p53?Thorsten Zenz, Stephan Stilgenbauer
Best Practice & Research. Clinical Haematology|November 29, 2015
BRAF inhibitor therapy in HCLSascha Dietrich, Thorsten Zenz
Haematologica|May 3, 2020
Genetics of "high-risk" chronic lymphocytic leukemia in the times of chemoimmunotherapyAlexander Ring, Thorsten Zenz
Leukemia & Lymphoma|August 25, 2009
Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survivalThorsten Zenz, Stephan Stilgenbauer
Hematology. American Society of Hematology. Education Program|January 18, 2011
Understanding and managing ultra high-risk chronic lymphocytic leukemiaStephan Stilgenbauer, Thorsten Zenz
Deutsche Medizinische Wochenschrift (1946)|June 13, 2015
[Hairy cell leukemia]Sascha Dietrich, Thorsten Zenz
Pageof 19

Showing results (1-10 of 183) with videos related to

Sort By:
Pageof 19
Blood|March 2, 2013
Exhausting T cells in CLLThorsten Zenz
Blood|October 31, 2015
Mutational landscape and complexity in CLLThorsten Zenz, Wolfgang Huber
British Journal of Haematology|June 13, 2022
GOALs in relapsed DLBCLWiebke Rösler, Thorsten Zenz
Leukemia & Lymphoma|August 16, 2012
Improving treatment for chronic lymphocytic leukemia by rational use of monoclonal antibodiesMikołaj Słabicki, Thorsten Zenz
Blood|August 14, 2010
CLL 17p deletion: more than 'miR'ly p53?Thorsten Zenz, Stephan Stilgenbauer
Best Practice & Research. Clinical Haematology|November 29, 2015
BRAF inhibitor therapy in HCLSascha Dietrich, Thorsten Zenz
Haematologica|May 3, 2020
Genetics of "high-risk" chronic lymphocytic leukemia in the times of chemoimmunotherapyAlexander Ring, Thorsten Zenz
Leukemia & Lymphoma|August 25, 2009
Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survivalThorsten Zenz, Stephan Stilgenbauer
Hematology. American Society of Hematology. Education Program|January 18, 2011
Understanding and managing ultra high-risk chronic lymphocytic leukemiaStephan Stilgenbauer, Thorsten Zenz
Deutsche Medizinische Wochenschrift (1946)|June 13, 2015
[Hairy cell leukemia]Sascha Dietrich, Thorsten Zenz
Pageof 19